Device Trial Radar · NCT02682420
everlinQ endoAVF Post Market Study
Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
100
Actual
Start
Sep 20, 2016
Primary completion
Aug 2019
Study completion Aug 2019
Sponsor
- Lead sponsor
- C. R. BardPublic (BDX)
- Sponsor type
- Industry
- First posted
- Feb 15, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multi-center study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for hemodialysis.
Conditions
- Chronic Kidney Disease
Interventions
everlinQ endoAVF SystemDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Primary Patency of the endoAVF at 6 Months Post-Index ProcedureTime frame: endoAVF creation through 6 months
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Providence Health Care Society
Vancouver, British Columbia, Canada
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.